AI drug discovery startup BenevolentAI cuts 30% of staff, closes US office
BenevolentAI is making its second round of layoffs in a year, as the company continues to refine the business strategy around its AI drug discovery platform.
Having completed a market assessment, BenevolentAI said it will cease work on a software-as-a-service product it called knowledge exploration tools, given the investment and time needed to fully commercialize the product and reap a financial return.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
